• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒病 2019(COVID-19):作用机制、检测和最近的治疗策略。

The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.

机构信息

Anatomical Sciences Research Center, Basic Sciences Research Institute, Kashan University of Medical Sciences, Kashan, Iran; Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran.

Department of Radiology, Faculty of Medicin, Kashan University of Medical Sciences, Kashan, Iran.

出版信息

Virology. 2020 Dec;551:1-9. doi: 10.1016/j.virol.2020.08.011. Epub 2020 Sep 24.

DOI:10.1016/j.virol.2020.08.011
PMID:33010669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7513802/
Abstract

Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β-coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously. Currently, antiviral inhibitors of SARS and MERS spike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, α-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs with their effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.

摘要

新型冠状病毒 SARS-CoV-2,世界卫生组织(WHO)于 2020 年 2 月 11 日指定为 COVID-19,是感染人类的高致病性β冠状病毒之一。COVID-19 的早期诊断是治疗感染的最关键步骤。诊断工具通常是分子方法、血清学和病毒培养。最近,基于 CRISPR 的方法已被用于诊断和治疗冠状病毒感染。2019 年新型冠状病毒在流感季节的出现,导致了抗生素和神经氨酸酶抑制剂的广泛使用,包括口服和静脉注射。目前,针对 SARS-CoV-2 感染个体的治疗选择包括 SARS 和 MERS 刺突蛋白的抗病毒抑制剂、神经氨酸酶抑制剂、抗炎药物和 EK1 肽。此外,先前用于治疗疟疾和自身免疫性疾病的氯喹在 2019 年新型冠状病毒感染治疗中显示出疗效。在严重低氧血症的情况下,抗生素联合使用、α-干扰素、洛匹那韦和机械通气可以有效缓解症状。对固有和适应性免疫反应的综合了解,将有可能提出有效的抗病毒药物及其治疗措施,以预防病毒感染。这种治疗策略将帮助全球患者保护自己免受严重和致命的病毒感染,这些感染可能会进化并产生耐药性,并降低死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/f69754e0baa7/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/bb834eea86b9/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/2eecc7aa9b20/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/0324b3d6d219/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/96352cf14533/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/f69754e0baa7/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/bb834eea86b9/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/2eecc7aa9b20/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/0324b3d6d219/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/96352cf14533/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cff9/7513802/f69754e0baa7/gr4_lrg.jpg

相似文献

1
The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.新型冠状病毒病 2019(COVID-19):作用机制、检测和最近的治疗策略。
Virology. 2020 Dec;551:1-9. doi: 10.1016/j.virol.2020.08.011. Epub 2020 Sep 24.
2
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.SARS-CoV-2 及其他人类致病冠状病毒的抗病毒药物和可用药靶的现状。
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
3
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
4
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.用于 SARS-CoV-2 治疗的潜在抗病毒药物:临床前发现和正在进行的临床研究。
In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949.
5
A global treatments for coronaviruses including COVID-19.全球针对冠状病毒(包括 COVID-19)的治疗方法。
J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11.
6
The broad-spectrum antiviral recommendations for drug discovery against COVID-19.广谱抗病毒药物研发应对 COVID-19 的建议。
Drug Metab Rev. 2020 Aug;52(3):408-424. doi: 10.1080/03602532.2020.1770782. Epub 2020 Jun 17.
7
T-cell responses and therapies against SARS-CoV-2 infection.T 细胞应答与针对 SARS-CoV-2 感染的治疗方法。
Immunology. 2021 Jan;162(1):30-43. doi: 10.1111/imm.13262. Epub 2020 Oct 27.
8
SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.SARS-CoV-2 与人类宿主的多方面相互作用。第一部分:迄今为止我们所了解和所做的,以及仍然未知的现实。
IUBMB Life. 2020 Nov;72(11):2313-2330. doi: 10.1002/iub.2380. Epub 2020 Sep 12.
9
Bacterial co-infections with SARS-CoV-2.细菌合并感染 SARS-CoV-2。
IUBMB Life. 2020 Oct;72(10):2097-2111. doi: 10.1002/iub.2356. Epub 2020 Aug 8.
10
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.

引用本文的文献

1
Advances in Plant-Derived Extracellular Vesicle Extraction Methods and Pharmacological Effects.植物源细胞外囊泡提取方法及药理作用的研究进展
Biology (Basel). 2025 Apr 6;14(4):377. doi: 10.3390/biology14040377.
2
Identification of potential hub genes and drugs in septic kidney injury: a bioinformatic analysis with preliminary experimental validation.脓毒症性肾损伤中潜在枢纽基因和药物的鉴定:一项具有初步实验验证的生物信息学分析
Front Med (Lausanne). 2025 Mar 17;12:1502189. doi: 10.3389/fmed.2025.1502189. eCollection 2025.
3
Broad-Spectrum Adverse Events of Special Interests Based on Immune Response Following COVID-19 Vaccination: A Large-Scale Population-Based Cohort Study.

本文引用的文献

1
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives.新型冠状病毒肺炎:流行病学、进化与跨学科视角。
Trends Mol Med. 2020 May;26(5):483-495. doi: 10.1016/j.molmed.2020.02.008. Epub 2020 Mar 21.
3
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.精准皮质类固醇治疗对重症2019新型冠状病毒肺炎的潜在益处。
基于新冠病毒疫苗接种后免疫反应的特殊关注的广谱不良事件:一项基于大规模人群的队列研究
J Clin Med. 2025 Mar 6;14(5):1767. doi: 10.3390/jcm14051767.
4
THYROID FUNCTION IN PATIENTS WITH COVID-19: A RETROSPECTIVE STUDY.新型冠状病毒肺炎患者的甲状腺功能:一项回顾性研究。
Acta Clin Croat. 2023 Dec;62(4):623-626. doi: 10.20471/acc.2023.62.04.6.
5
Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in East Asia and the Pacific Region: Longitudinal Trend Analysis.东亚及太平洋地区2019冠状病毒病大流行(2020 - 2023年)的最新监测指标与历史:纵向趋势分析
JMIR Public Health Surveill. 2025 Feb 21;11:e53214. doi: 10.2196/53214.
6
Neuropathic component of chronic musculoskeletal pain in patients with post-COVID-19: A cross-sectional study.新冠病毒感染后患者慢性肌肉骨骼疼痛的神经病理性成分:一项横断面研究。
Arch Rheumatol. 2024 Aug 26;39(3):436-446. doi: 10.46497/ArchRheumatol.2024.9990. eCollection 2024 Sep.
7
Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Canada: Longitudinal Trend Analysis.加拿大2019冠状病毒病大流行(2020 - 2023年)的最新监测指标与历史:纵向趋势分析
JMIR Public Health Surveill. 2024 Dec 5;10:e53218. doi: 10.2196/53218.
8
Epigenetic changes in patients with post-acute COVID-19 symptoms (PACS) and long-COVID: A systematic review.急性 COVID-19 后症状(PACS)和长 COVID 患者的表观遗传变化:系统评价。
Expert Rev Mol Med. 2024 Oct 22;26:e29. doi: 10.1017/erm.2024.32.
9
The Predictive Performance of Risk Scores for the Outcome of COVID-19 in a 2-Year Swiss Cohort.瑞士一个为期两年的队列研究中COVID-19结局风险评分的预测性能
Biomedicines. 2024 Jul 31;12(8):1702. doi: 10.3390/biomedicines12081702.
10
The Effect of Coronavirus Disease 2019 on the Quality of Associated Care in Patients with Gastric Cancer.2019年冠状病毒病对胃癌患者相关护理质量的影响。
Middle East J Dig Dis. 2024 Jan;16(1):12-22. doi: 10.34172/mejdd.2024.363. Epub 2024 Jan 31.
Signal Transduct Target Ther. 2020 Feb 21;5(1):18. doi: 10.1038/s41392-020-0127-9.
4
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病(COVID-19)疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
5
Identification of Coronavirus Isolated from a Patient in Korea with COVID-19.从韩国一名新冠肺炎患者身上分离出的冠状病毒的鉴定。
Osong Public Health Res Perspect. 2020 Feb;11(1):3-7. doi: 10.24171/j.phrp.2020.11.1.02.
6
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒(2019-nCoV)的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
7
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局:一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
8
Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses.以毒攻毒:一种针对2019新型冠状病毒(SARS-CoV-2)及其他RNA病毒的潜在疗法。
Cell Res. 2020 Mar;30(3):189-190. doi: 10.1038/s41422-020-0290-0.
9
Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing.胸部 CT 与典型 2019 冠状病毒病(COVID-19)肺炎:与阴性 RT-PCR 检测的关系。
Radiology. 2020 Aug;296(2):E41-E45. doi: 10.1148/radiol.2020200343. Epub 2020 Feb 12.
10
Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion.胸部CT联合2019新型冠状病毒逆转录聚合酶链反应检测结果为阴性但临床高度怀疑的应用
Radiology. 2020 Apr;295(1):22-23. doi: 10.1148/radiol.2020200330. Epub 2020 Feb 12.